Skip to main content
. Author manuscript; available in PMC: 2019 Sep 4.
Published in final edited form as: ACS Pharmacol Transl Sci. 2019 Jul 17;2(4):247–263. doi: 10.1021/acsptsci.9b00020

Figure 4. Combination treatment displays additive mis-splicing rescue in HSALR DM1 mouse model.

Figure 4.

Splicing analysis of ES events determined via RNA-seq on HSALR mice treated with 600 mg kg−1 erythromycin (EM, green) or 10 mg kg−1 pafuramidine (PaF, blue) or a combination of both (EM+PaF, magenta) per oral administration daily for 14 days. (A) Dcaf6 exon12 (B) Ldb3 exon11, (C) Mpdz exon27 and (D) Wrd7 exon17 mis-splicing events displayed greater rescue with combination treatment. Mean % rescue ± standard deviation values are displayed below each graph.